Effects of Escitalopram in treatment of patients with obsession

Clinical trial of comparing the effects of Escitalopram with Setraline on the severity of signs and symptoms of patients with obsessive compulsive disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016020421745N4

Enrollment

Registered

2016-04-20

Start date

2016-04-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obsessive compulsive disorder. The essential feature is recurrent obsessional thoughts or compulsive acts. Obsessional thoughts are ideas, images, or impulses that enter the patient's mind again and again in a stereotyped form. They are almost invariably distressing and the patient oft

Interventions

Intervention 1: Intervention group (group A) will receive Escitalopram for 6 weeks. Escitalopram tablets are 10mg tablets that are produced by Hakim pharmaceutical company. Making all tablets the same

Treatment - Drugs

Intervention group (group A) will receive Escitalopram for 6 weeks. Escitalopram tablets are 10mg tablets that are produced by Hakim pharmaceutical company. Making all tablets the same series.The init

Control group (group B) will receive Sertraline for 6 weeks. Sertraline tablets are 50mg tablets that are produced by Sobhandaroo pharmaceutical company. Making all tablets the same series.The initial

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with obsessive compulsive disorder (OCD) that diagnosed with interview by psychiatrist according to DSM-IV TR; Yale-Brown-obsessive-compulsive scale equal or more than 18; Informed consent of patients. Exclusion criteria: Other psychiatric disorder diagnosis according to axis I and II; Major medical illness like hypertension, diabetes, cardiovascular disease, renal disease and gastrointestinal disease; Pregnancy and lactation; Substance or alcohol abuse; Any intolerable adverse side effects of treatment; Any SSRI usage in past 5 weeks; Patients younger than 18 years and older than 65 years old.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of signs and symptoms of the patients with obcessive compulsive disorder. Timepoint: At the beginning of study and at the sixth week of study. Method of measurement: Y-BOCS At the beginning of study and at the sixth week of study and CGI-Improvement test at sixth week of study.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Modaresi

Shiraz University of Medical Sciences

drfarzanehmodaresi84@yahoo.com+98 71 3627 9319

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026